MDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study Jennifer M. Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman6, Kelly Parker-Guilbert7, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman 11, Christopher Nicholas12, Michael Mithoefer5,9,13, Shannon Carlin, Bruce Poulter 8,9, Ann Mithoefer9, Sylvestre Quevedo2,14, Gregory Wells 14, Sukhpreet S. Klaire, Bessel van der Kolk16, Keren Tzarfaty9, Revital Amiaz17, Ray Worthy18, Scott Shannon, Joshua D. Woolley2, Cole Marta20, Yevgeniy Gelfand21, Emma Hapke, Simon Amar, Yair Wallach, Randall Brown11, Scott Hamilton25, Julie B. Wang5, Allison Coker 1,5, Rebecca Matthews, Alberdina de Boer5, Berra Yazar-Klosinski, Amy Emerson and Rick Doblin Nature Medicine | www.nature.com/naturemedicine, 2021, 1-12. doi : [...]
Lire la suiteCannabidiol (CBD) repurposing as antibacterial: promising therapy of 1 CBD plus polymyxin B against superbugs Nathália Abichabki, Luísa V. Zacharias, Natália C. Moreira, Fernando Bellissimo-Rodrigues, Fernanda L. Moreira, Jhohann R. L. Benzi1, Tânia M. C. Ogasawara, Joseane C. Ferreira, Leonardo R. L. Pereira, Gilberto Ú. L. Braga, Camila M. Ribeiro, Fernando R. Pavan, Antonio W. Zuardi, Jaime E. C. Hallak, José A. S. Crippa, Vera L. Lanchote, Rafael Cantón, Ana Lúcia C. Darini, Leonardo N. Andrade bioRxiv preprint, 2021 doi : 10.1101/2021.04.12.439341 Abstract : Multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are a major worldwide public health problem. In the last decades, resistance to [...]
Lire la suiteAnalyse et position de NORML France sur les produits dérivés chanvre CBD NORML France, par Olivier Bertrand | Juin 13, 2018 | https://www.norml.fr/la-position-de-norml-france-sur-le-chanvre-cbd-et-les-nouvelles-boutiques-chanvre/ Alors que les fleurs de chanvre industrielles étaient méprisées du grand public jusqu’à récemment, les voici désormais sous les phares des projecteurs médiatiques avec la vague de nouvelles boutiques CBD qui déferle sur la France actuellement. Par quel miracle transforme t-on un déchet de l’agriculture du chanvre en un produit hautement valorisable ? Pourquoi un tel engouement pour un produit qui n’intéressait naguère absolument personne? Le cannabidiol, la nouvelle substance active en vogue du cannabis. La construction moléculaire du CBD, très proche [...]
Lire la suiteLes recommandations de NORML France à la Mission d’Information Cannabis de l’Assemblée Nationale NORML France, par Le Collectif | Avr 20, 2021 | https://www.norml.fr/nos-recommandations-mission-information-cannabis-an/ Nos propositions ont été adressées en février de cette année à la Mission d’information “Réglementation et impact des différents usages du cannabis” de l’Assemblée Nationale. Ce même document de 22 recommandations sera envoyé par email à l’ensemble de nos députés et sénateurs cette semaine. Vous pouvez le retrouver dans sa version complète comme dans sa version courte sur cette page. CANNABIS : VERS UNE RÉGULATION BÉNÉFIQUE AUX USAGERS ET À LA SOCIÉTÉ. 📗 Téléchargez la note complète Cette note est le fruit d’un [...]
Lire la suiteTrial of Psilocybin versus Escitalopram for Depression Robin Carhart-Harris, Ph.D., Bruna Giribaldi, B.Sc., Rosalind Watts, D.Clin.Psy., Michelle Baker-Jones, B.A., Ashleigh Murphy-Beiner, M.Sc., Roberta Murphy, M.D., Jonny Martell, M.D., Allan Blemings, M.Sc., David Erritzoe, M.D. and David J. Nutt, M.D.New England Journal of Medicine, 2021, 384, 1402-1411Doi : 10.1056/NEJMoa2032994 Abstract Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive [...]
Lire la suitePsilocybin for treatment-resistant depression : fMRI-measured brain mechanisms Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran & David J Nutt Nature, Scientific Reports, 2017, 7, 13187 |1-11 Doi : 10.1038/s41598-017-13282-7 Abstract Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). [...]
Lire la suiteUn grand débat sur une politique de régulation des drogues publié le 19/04/2021 | Communiqué du 19 avril 2021 La Fédération Addiction appelle depuis longtemps à un grand débat sur la régulation des substances psychoactives tant en termes de santé que de sécurité. Le président de la République dresse le constat que « la France est devenue un pays de consommation ». La pénalisation de l’usage de drogues illégales n’a pourtant jamais été remise en cause depuis 51 ans, notre législation reste une des plus sévères et l’application des sanctions n’a cessé de se renforcer. Tout cela est parfaitement documenté par les travaux de l’OFDT et OEDT[1]. Sur la même période, prévention et réduction [...]
Lire la suitePsilocybin Delivers ‘Remarkable’ Relief in Severe Depression, Batya Swift Yasgur, Medscape.com, 2020
Psilocybin Delivers 'Remarkable' Relief in Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News, November 05, 2020 Psilocybin, the psychedelic compound in "magic mushrooms," rapidly improves symptoms and produces remission in as little as two sessions for patients with major depression, new research suggests. Results of a small randomized trial showed that treatment with psilocybin was associated with a greater than 50% reduction in depressive symptoms in 67% of study participants. In addition, 71% showed improvement at 4-week follow-up, with more than 50% achieving remission. "The finding that the majority of people whom we treated showed efficacy was quite a remarkable and gratifying finding [...]
Lire la suitePsilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study Sarah Edmonds Medscape Medical News, April 14, 2021 The psychedelic drug psilocybin performed just as well as a widely used antidepressant in easing the symptoms of major depression, and outperformed the selective serotonin reuptake inhibitor (SSRI) on a range of secondary measures, results of a small-scale phase 2 study show. In a 6-week trial that included 59 patients with moderate-to-severe depression, there was no significant difference between the impact of high-dose psilocybin on the study's primary yardstick — the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) — and that of selective serotonin reuptake [...]
Lire la suite'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News © 2017 October 20, 2017 Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at 5 [...]
Lire la suite